Q3 EPS Forecast for IDEXX Laboratories Increased by Analyst

Key Points

• Leerink Partners has raised its earnings per share estimate for IDEXX Laboratories for Q3 2025 from $3.13 to $3.18, with the annual earnings estimate increased to $11.93.
• IDEXX Laboratories reported a quarterly earnings per share of $3.63, exceeding analysts' expectations by $0.35, with revenue of $1.11 billion, up 10.6% year-over-year.
• Multiple analysts have revised their price targets for IDEXX Laboratories, with JPMorgan raising their target from $550 to $675, and BTIG Research increasing theirs from $545 to $785, indicating strong investor confidence.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) - Research analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for IDEXX Laboratories in a report released on Monday, August 4th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $3.18 for the quarter, up from their prior estimate of $3.13. The consensus estimate for IDEXX Laboratories' current full-year earnings is $11.93 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories' FY2025 earnings at $12.68 EPS, FY2026 earnings at $14.29 EPS, FY2027 earnings at $16.03 EPS and FY2028 earnings at $17.95 EPS.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%. IDEXX Laboratories's revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.44 earnings per share.

IDXX has been the subject of a number of other reports. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a report on Monday. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Jefferies Financial Group started coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price objective for the company. Morgan Stanley set a $722.00 price objective on IDEXX Laboratories and gave the company an "overweight" rating in a research report on Tuesday. Finally, Leerink Partners boosted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $623.56.

IDEXX Laboratories Price Performance

IDXX stock traded up $25.87 during midday trading on Wednesday, reaching $650.06. The company had a trading volume of 798,751 shares, compared to its average volume of 789,096. The firm has a 50-day moving average price of $542.32 and a 200-day moving average price of $477.73. The company has a market capitalization of $52.00 billion, a P/E ratio of 54.13, a P/E/G ratio of 4.03 and a beta of 1.49. IDEXX Laboratories has a 1 year low of $356.14 and a 1 year high of $688.12. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.81.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its holdings in shares of IDEXX Laboratories by 39.5% during the fourth quarter. Russell Investments Group Ltd. now owns 70,314 shares of the company's stock valued at $29,066,000 after acquiring an additional 19,917 shares in the last quarter. Federated Hermes Inc. increased its position in IDEXX Laboratories by 3.1% during the 4th quarter. Federated Hermes Inc. now owns 57,979 shares of the company's stock valued at $23,971,000 after purchasing an additional 1,725 shares during the period. Cerity Partners LLC increased its position in IDEXX Laboratories by 4.3% during the 4th quarter. Cerity Partners LLC now owns 11,395 shares of the company's stock valued at $5,073,000 after purchasing an additional 471 shares during the period. Bank of Montreal Can raised its holdings in IDEXX Laboratories by 3.9% in the 4th quarter. Bank of Montreal Can now owns 120,276 shares of the company's stock worth $49,727,000 after purchasing an additional 4,511 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after purchasing an additional 74,324 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director owned 1,801 shares of the company's stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.98% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.